Background: Tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7), inducers of G 1 cell cycle arrest, are two recently discovered good biomarkers for early diagnosis of acute kidney injury (AKI). To obtain a more robust performance measurement, the present meta-analysis was performed, pooling existing studies.
and considered to be superior to NGAL, KIM-1, and L-FABP [8] . Both TIMP-2 and IGFBP7 are inducers of G 1 cell cycle arrest, considered a key mechanism of AKI [9] . Kashani and colleagues [8] [10, 11] . Therefore, the present meta-analysis was performed to obtain a more robust performance measurement of [TIMP-2] × [IGFBP7] for early detection of AKI with more reliable evidence for clinical decision making.
Methods

Data sources and search strategy
A protocol of complete meta-analysis was constructed and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards [12] . The protocol was registered with the PROSPERO database (registration number CRD42016051186).
Two investigators (HMJ and LFH) independently searched the literature in the MEDLINE (via PubMed search engine), Ovid, Embase, and Cochrane Library electronic databases from inception to 12 October 2016. Text words or medical subject headings containing "tissue inhibitor of metalloproteinase-2," "TIMP-2," "insulin-like growth factor binding protein 7," "IGFBP7," "acute kidney injury," "AKI," "acute renal failure," "ARF," "acute kidney disease," and "acute kidney stress" were researched without language restriction. Additional studies were identified by reviewing the reference lists of relevant articles.
Study selection criteria
Two investigators (HMJ and LFH) independently screened the records obtained from the databases. Studies were included if they met the following three criteria:
1. Original clinical studies with participants over the age of 18 years (without restriction for study design) 2. Detection of urinary [TIMP-2] × [IGFBP7] used for early diagnosis of AKI 3. Development of AKI diagnosed by the criteria of risk, injury, failure, loss, end-stage kidney disease (RIFLE); the Acute Kidney Injury Network; or KDIGO [13] [14] [15] Original human studies were excluded if they had insufficient information for true-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) results. Repeated reports based on the same study data were also excluded. All retrieved articles were initially screened by title and abstract. The relevant ones were subsequently rescreened by full text. A third party resolved any discrepancies between two investigators (HMJ and LFH) in the process of study selection.
Data extraction and quality assessment
Two investigators (HMJ and LFH) independently extracted study characteristics and data from individual reports, including first author, year of publication, study location, study design, population setting, AKI definition, sample size, sampling time of urine specimens, assay of urine TIMP-2 and IGFBP7, and numbers of AKI and non-AKI patients. Meanwhile, TP, FP, FN, TN, sensitivity, specificity, AUC, and optimal cutoff value of urinary [TIMP-2] × [IGFBP7] for early diagnosis of AKI were recorded. If multiple time points of urine measurements were used for AKI diagnosis, the one with the highest AUC was recorded. Similarly, if multiple cutoff values were obtained via AUC analysis, the one showing the highest Youden index was recorded.
Two investigators (HMJ and LFH) independently assessed the methodological quality of eligible studies using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool [16] . QUADAS-2, focusing on risk of bias in the accuracy and applicability of original articles, consists of four domains: patient selection, index test, reference standard, and flow and timing. Each domain assesses the risk of bias by representative questions whose corresponding answers may be "yes," "no," or "unclear." If all answers were "yes" in one domain, low risk of bias was considered. Any "no" in one domain indicated a high risk of bias. Studies not providing sufficient information to answer "yes" or "no" in the domain reflected unclear risk of bias. Methods used to assess the applicability of studies are the same as those of risk of bias. A third party resolved any discrepancies between two investigators (HMJ and LFH) in the process of data extraction and quality assessment.
Statistical analysis
Meta-DiSc 1.4 software was used for statistical analysis. A random-effects model (DerSimonian and Laird method) or fixed-effects model (Mantel-Haenszel method) was constructed to estimate pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) with 95% CI. Model selection was based on the heterogeneity of included studies [17, 18] . Heterogeneity induced by threshold effect was reflected by a typical shape of a "shoulder-arm" in the summary receiver operating characteristic (SROC) plane or p < 0.05 in Spearman's correlation coefficient test.
Heterogeneity induced by a nonthreshold effect was evaluated by Cochran's Q test and I 2 test; Cochran's Q test with p < 0.10 indicated heterogeneity, whereas different I 2 values reflected low (<30%), moderate (30% to 50%), and high (>50%) degrees of heterogeneity. To identify the causes of heterogeneity in eligible studies, sensitivity and subgroup analyses were performed. The stability of results was examined by omitting one study at a time in sensitivity analysis; different subgroups based on potential sources of heterogeneity were considered in subgroup analysis. The SROC curve was used to estimate AUC [19] , with a value ≥0.70 considered to reflect a useful predictive factor. Publication bias was assessed via funnel plot using Review Manager 5.3 software [20] .
Results
Study selection and characteristics
A flow diagram summarizing the study selection process is presented in Fig. 1 2 /1000. Notably, population settings were different in the nine studies, including postoperative cardiac patients, critically ill individuals in the ICU, and patients in the emergency department (ED) [7, [21] [22] [23] [24] [25] [26] [27] [28] . The full KDIGO criteria were used to diagnose AKI in all nine studies, but AKI thresholds were different. Three studies defined primary clinical endpoint as patients meeting KDIGO stage 1 criteria. The remaining six studies considered the primary endpoint as patients meeting KDIGO stage 2 or 3 criteria. Urinary [TIMP-2] × [IGFBP7] was evaluated for AKI prediction within 12 h in four studies, within 48 h in four studies, and within 72 h in one study. The characteristics of individual studies are shown in Table 1 .
Quality assessment
Study quality concerning each domain for individual studies is depicted in Fig. 2 . Funnel plot (Fig. 3 ) results indicated a publication bias in the included studies.
Data synthesis
Data extracted from the nine eligible studies are summarized in Table 2 was 0.46 with p > 0.05, indicating there was no significant threshold effect in the nine studies. This result was also confirmed by the shape without a "shoulderarm" in the SROC plane. In assessing the nonthreshold effect, pooled DOR (I 2 = 38.5%) and NLR (I 2 = 43.4%) showed moderate heterogeneity, whereas sensitivity (I 2 = 68.8%), specificity (I 2 = 92.9%), and PLR (I 2 = 82.6%) indicated significantly high heterogeneity. A random-effects model was used to pool the data. Pooled sensitivity and specificity were 0.83 (95% CI 0.79-0.87) and 0.55 (95% CI 0.52-0.57), respectively. Pooled PLR, NLR, and DOR were 2.37 (95% CI 1.87-2.99), 0.30 (95% CI 0.21-0.41), and 9.92 (95% CI 6.06-16.18), respectively. Estimated AUC was 0.846 (SE 0.027) with Q* of 0.777 (SE 0.026). The pooled sensitivity, specificity, PLR, and NLR for the nine studies are presented in Fig. 4 .
In sensitivity analysis, the study by Dusse and colleagues [28] Fig. 5 . Pooled sensitivity, specificity, PLR, and NLR for the eight studies are presented in Fig. 6 .
Subgroup analysis was conducted based on population setting, AKI threshold, and blinding status. The results showed that population setting and AKI threshold were key factors causing heterogeneity. The 9 studies were divided into two subgroups according to different population settings. A total of 4 studies focused on patients undergoing cardiac surgery, and were termed the "cardiac surgery" subgroup. 4 others focused on patients in the ICU and 1 on patients in the ED, and constituted the "ICU and ED" subgroup. Interestingly, urinary [TIMP-2] × [IGFBP7] showed an excellent diagnostic value in patients undergoing cardiac surgery with estimated AUC of 0.911. Pooled sensitivity and specificity were 0.75 (95% CI 0.62-0.86, I 2 = 69.8%) and 0.87 (95% CI 0.80-0.92, I 2 = 33.9%), respectively. In the "ICU and ED" subgroup, estimated AUC was 0.814; pooled sensitivity and specificity were 0.85 (95% CI 0.80-0.89, I 2 = 68.5%) and 0.51 (95% CI 0.49-0.54, I 2 = 89.2%), respectively. Similarly, the 9 studies were divided into "KDIGO stage 2 or 3" and "KDIGO stage 1" subgroups according to the different AKI thresholds mentioned above. There were 6 studies in the "KDIGO stage 2 or 3" subgroup; estimated AUC was 0.813, while pooled sensitivity and specificity were 0.88 (95% CI 0.83-0.91, I 2 = 38.9%) and 0.52 (95% CI 0.49-0.55, I 2 = 89.8%), respectively. There were 3 studies in the "KDIGO stage 1" subgroup; estimated AUC was 0.868, with pooled sensitivity and specificity of 0.70 (95% CI 0.59-0.79, I 2 = 54.3%) and 0.88 (95% CI 0.80-0.93, I 2 = 31.7%), respectively. The results of subgroup analysis are shown in Table 3 . Fig. 2 Quality assessment summary in each domain for individual studies. The quality assessment focusing on risk of bias and applicability concerns consists of four domains, including "patient selection," "index test," "reference standard," and "flow and timing." Green, yellow, and red indicate low, moderate, and high risk of bias, respectively 
Discussion
AKI remains one of the most common and serious clinical syndromes, and it is associated with high morbidity and mortality in critically ill patients. Current diagnosis of AKI is based on serum creatinine and urine output, despite known limitations of these markers. Diverse platforms and multiple studies have explored future biomarkers for early prediction of AKI [29] . In order to obtain a more robust performance measurement of urinary [TIMP-2] × [IGFBP7] for AKI, this meta-analysis was performed, also pooling existing studies. A total of 9 published and eligible studies assessing 1886 cases were included. The results indicated that urinary [TIMP-2] × [IGFBP7] is an effective predictive factor of AKI.
Dusse and colleagues demonstrated an excellent predictive value of urinary [TIMP-2] × [IGFBP7]
for AKI in patients undergoing transcatheter aortic valve implantation (TAVI). An AUC of 0.97 was obtained, with sensitivity and specificity of 100% and 91%, respectively. However, sensitivity analysis showed that this study could result in significant heterogeneity in pooled DOR. Its small sample size and the specific population setting were considered important issues that can lead to heterogeneity. On one hand, the small sample size of 40 patients was likely to cause publication bias. On the other hand, patients undergoing TAVI are at high risk of developing AKI, which is probably associated with hypotension occurrence, There are studies indicating that cardiac surgery with cardiopulmonary bypass could lead to reduced renal blood flow as well as surgical trauma, which probably damage kidney function or structure [32, 33] . Fortunately, with the development of innovative technologies such as renal Doppler ultrasound, renal blood flow and cortical microcirculation can be dynamically monitored at the bedside, which may help manage hemodynamics and decrease the incidence of ischemic AKI [34] . Further clinical trials are still required to confirm the diagnostic value of urinary [TIMP-2] × [IGFBP7] for AKI in patients undergoing noncardiac surgery.
The diagnostic value of urinary [TIMP-2] × [IGFBP7] was also influenced by different AKI thresholds. AUC was higher in the KDIGO stage 1 subgroup than in the KDIGO stage 2 or 3 subgroup (0.868 vs. 0.813). However, pooled sensitivity was lower in the KDIGO stage 1 (0.70) compared with that of the KDIGO stage 2 or 3 subgroup (0.88). The main causes may be that TIMP-2 and IGFBP7, reflecting the stress status of the kidney, are more relevant to kidney damage. AKI diagnosed by KDIGO stage 1 criteria, possibly with FP results, is affected by many factors of hemoconcentration, drugs, and reversible oliguria, which may not develop real kidney stress and damage. Although KDIGO stage 2 or 3 reflects a moderate to severe AKI, renal cells are more likely to sustain insults by sepsis and ischemia that cause kidney damage [35, 36] . On the basis of this hypothesis, urinary [TIMP-2] × [IGFBP7] may be more sensitive for predicting AKI with KDIGO stage 2 or 3 than AKI with KDIGO stage 1.
TIMP-2 and IGFBP7 are two biomarkers of G 1 cell cycle arrest, indicating a preinjury status that leads to AKI [36] . AKI is related to the mechanisms of inflammation, oxidative stress, and apoptosis in cellular and molecular pathways [37, 38] . TIMP-2 and IGFBP7 can participate in these mechanisms and reflect early damage of the kidney [35] . They can regulate the activated p-protein cascade of p53, p21, and p27, subsequently blocking the effect of cyclin-dependent protein kinase complexes and altering the cellular response to the toxin or inflammatory factors [39] [40] [41] . Moreover, these two biomarkers may attempt to protect renal cells and avoid division, demise, or senescence [42, 43] . There is evidence showing that TIMP-2 and IGFBP7 are able to mark injured tubular epithelium and send signals in case of septic and ischemic insults, warning for kidney stress [44] . Then, renal tubular cells would enter for a short period G 1 cell cycle arrest to prevent injury aggravation [45, 46] [21] . These results suggested that a combination of clinical characteristics with specific biomarkers may enhance diagnostic accuracy in AKI. Like troponin, it constitutes an outstanding acute coronary syndrome biomarker when combined with typical symptoms and angina pectoris in specific populations. Similarly, there is renal angina (RA) in the AKI disorder. RA incorporates risk factors (e.g., advanced age, cardiopulmonary bypass, volume depletion, nephrotoxins) and symptomology (e.g., change of serum creatine, urine output, fluid overload) of patients to assess risk stratification for adult AKI. The renal angina index (RAI) is used for pediatric cohorts instead of RA to evaluate the risk for developing AKI by establishing point values [47, 48] . Clinical studies confirmed that a combined use of AKI biomarkers with RAI could improve the predictive value of the biomarkers for AKI [49] . Therefore, to a certain extent, this approach may be considerably potent for early prediction of AKI.
Serum creatinine and urine output were proposed by KDIGO for diagnosing AKI [15] . However, their use may inevitably result in inaccurate diagnosis of patients with AKI. Serum creatinine is readily available and specific for renal function. Nonetheless, it remains limited for AKI diagnosis. Serum creatinine can be affected by several factors, including age, diet, muscle mass, drugs, and creatinine's volume of distribution. With a delayed reaction, serum creatinine concentrations take 24 to 36 h to rise after kidney damage. Urine output is far less specific and can be influenced by diuretics; it persists until renal function almost ceases. Severe AKI can present as anuria, oliguria, and normal urine output, and oliguria can occur in volume depletion without AKI [13, 50, 51] . Such problems may result in the limitation of using serum creatinine and urine output as the gold standard for diagnosing AKI. 
